Skip to main content
Clinical Trials/NCT02791399
NCT02791399CompletedNot Applicable

A Patient-Centered Intervention to Improve Opioid Safety

VA Office of Research and Development1 site in 1 country286 target enrollmentStarted: March 23, 2016Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
286
Locations
1
Primary Endpoint
Current Opioid Misuse Measure (COMM)

Study Overview

Brief Summary

This is a randomized controlled trial of a multifaceted intervention designed to improve the safety of opioid prescribing. The specific aims of this study are to: (a) evaluate whether a multifaceted intervention (Improving the Safety of Opioid Prescribing; ISOP) enhances opioid safety, (b) assess whether participation in ISOP impacts the clinician-patient relationship, and (c) explore to what extent ISOP is associated with changes in pain and pain-related function.

Detailed Description

The investigators will randomize primary care providers (PCPs) at the VA Portland Health Care System to either ISOP or the control condition; patients will be nested by clinician status. All PCPs who enroll will participate in either a two-hour educational workshop or the two-hour educational workshop + nurse care manager (NCM). The NCM will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to PCPs for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse. The investigators will recruit patients who are already prescribed chronic opioid therapy for chronic non-cancer pain. Participants will be enrolled for one year. Outcomes will be measured at baseline, and 6 and 12 months after enrollment.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Enrollment in primary care at the VA Portland Health Care System
  • •Receiving long-term opioid therapy (for at least 3 months) for chronic pain unrelated to a life-limiting disease
  • •Able to read and write in English

Exclusion Criteria

  • •Age younger than 18 years old
  • •On opioid therapy for palliative or end-of-life care
  • •Current enrollment in an opioid substitution program
  • •Lack of access to a telephone

Arms & Interventions

Control

No Intervention

Treatment as usual

ISOP Intervention

Experimental

Primary care providers and PACT nurses will participate in the same workshop as those randomized to the control condition (or academic detailing for those unable to attend the workshop). Clinicians randomized to the intervention will additionally collaborate with a nurse care manager (NCM) who will maintain a registry of enrolled patients, track UDT administrations and results, query prescription drug monitoring databases, monitor other evidence of potential problems, and collaborate with expert consultants to provide decision support when patients have evidence of prescription opioid misuse or abuse. The NCM will also meet with patients to discuss methods to reduce opioid adverse effects, prevent misuse, and provide rationale for prescription opioid adherence monitoring.

Intervention: ISOP Intervention with the Nurse Care Manager (Behavioral)

Outcomes

Primary Outcomes

Current Opioid Misuse Measure (COMM)

Time Frame: Data collected at baseline, 6 months, and 12 months.

The Current Opioid Misuse Measure (COMM) is an assessment of self-reported risk of prescription opioid misuse. There are 17 items, each rated on a scale of 0 (never) to 4 (very often). Total scores range from 0 - 68, with higher scores indicating a greater risk of prescription opioid misuse.

Urine Drug Test

Time Frame: Data collected at baseline, 6 months, and 12 months

Participants will complete urine drug tests (UDTs) to evaluate for presence of substances. UDTs will evaluate for cannabis, cocaine, amphetamines, benzodiazepines, barbiturates, opioids, and opiates. Study results are dichotomous.

Secondary Outcomes

  • Chronic Pain Grade(One year)

Investigators

Sponsor Class
Fed
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials